natgillin/translations-raw huggingface dataset:
Date of first authorisation: 14 November 2007 Date of latest renewal: 01 October 2012 
Datum posljednje obnove odobrenja: 1. listopad 2012
Tell your doctor if you are taking, have recently taken or might take any other medicines. 
Obavijestite svog liječnika ako uzimate ili ste nedavno uzeli ili biste mogli uzeti bilo koje druge
Do not throw away any medicines via wastewater or household waste. 
Nemojte bacati bilo kakve lijekove odvode niti u kućni otpad.
Store below 30ºC. 
Čuvati ispod 30 º C.
As with other antipsychotics, it is recommended that blood pressure is measured periodically in patients over 65 years. 
Kao i s drugim antipsihoticima, preporučuje se povremeno mjerenje krvnog tlaka u bolesnika starijih od 65 godina.
Such factors possibly contribute to the higher average exposure observed in adolescents. 
Ti faktori moguće doprinose većoj prosječnoj izloženosti uočenoj u
Long-term outcomes associated with these events have not been studied and remain unknown (see sections 4.8 and 5.1). 
Dugoročni ishodi povezani s ovim događajima nisu proučavani i još su nepoznati (vidjeti dijelove 4.8 i 5.1).
Talk to your doctor or pharmacist before you take OLANZAPINE CIPLA. 
Obratite se svom liječniku ili ljekarniku prije nego uzmete lijek OLANZAPINE CIPLA.
Do not use this medicine after the expiry date which is stated on the carton after Exp. Store in the original package. 
Nemojte koristiti ovaj lijek nakon isteka roka valjanosti navedenog na pakovanju nakon Exp.
There are no data on maintenance of effect and limited data on long term safety (see sections 4.4 and 4.8). 
Ne postoje podaci o održavanju učinka i ograničeni su podaci o dugotrajnoj sigurnosti (vidjeti dijelove 4.4 i 4.8).
You should take your OLANZAPINE CIPLA tablets once a day following the advice of your doctor. 
OLANZAPINE CIPLA tablete morate uzimati jednom dnevno pridržavajući se savjeta svog liječnika.
In a study of Caucasians, Japanese, and Chinese subjects, there were no differences in the pharmacokinetic parameters among the three populations. 
U ispitivanju na bijelcima, Japancima i Kinezima nisu postojale razlike u farmakokinetičkim
Smokers The starting dose and dose range need not be routinely altered for non-smokers relative to smokers. 
Početna doza i raspon doze ne moraju se rutinski mijenjati za nepušače u odnosu na pušače.
• iIf you are allergic (hypersensitive) to olanzapine or any of the other ingredients of this medicine (listed in section 6). 
• Ako ste alergični (preosjetljivi) na olanzapin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.ema.europa.eu/. 
Detaljnije informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove http://www.ema.europa.eu.
• Whenever the risk management system is modified,especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached 
• Uoči svake izmjene sustava za upravljanje rizicima, a naročito kada je ta izmjena rezultat primitka novih informacija koje mogu voditi ka značajnim izmjenama omjera korist/rizik, odnosno kada je omjer korist/rizik rezultat ostvarenja nekog važnog cilja (u smislu
An increase to a dose greater than the recommended starting dose is advised only after appropriate clinical reassessment and should generally occur at intervals of not less than 24 hours. 
Povećanje doze iznad preporučene početne doze savjetuje se samo nakon odgovarajuće ponovne kliničke procjene i treba općenito nastupiti u intervalima ne kraćima od 24 sata.
Dementia-related psychosis and/or behavioural disturbances Olanzapine is not approved for the treatment of dementia-related psychosis and/or behavioural disturbances and is not recommended for use in this particular group of patients because of an increase in mortality and the risk of cerebrovascular accident. 
Psihoza i/ili poremećaji ponašanja uzrokovani demencijom Olanzapin nije odobren za liječenje psihoze i/ili poremećaja ponašanja uzrokovanih demencijom te se njegova primjena ne preporučuje u ovoj specifičnoj skupini bolesnika zbog porasta mortaliteta i rizika od pojave cerebrovaskularnog događaja.
Pharmacotherapeutic group: diazepines, oxazepines and thiazepines., ATC code: N05A H03. 
Farmakoterapijska skupina: diazepini, oksazepini i tiazepini, ATK oznaka: N05AH03.
Ventricular tachycardia/fibrillation , sudden death (see section 4.4)11 
ventrikularna tahikardija/fibrilacija, iznenadna smrt (vidjeti dio 4.4)11
In cases of moderate hepatic insufficiency (cirrhosis, Child-Pugh Class A or B), the starting dose should be 5 mg and only increased with caution. 
U slučajevima umjerene insuficijencije jetre (ciroza, Child-Pugh stadij A ili B), početna doza treba biti 5 mg i može se povećati samo uz
• carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your OLANZAPINE CIPLA dose. 
• karbamazepin (antiepileptik i stabilizator raspoloženja), fluvoksamin (antidepresiv) ili ciprofloksacin (antibiotik) - možda će biti potrebno promijeniti dozu lijeka OLANZAPINE
What you need to know before you take OLANZAPINE CIPLA 
Što morate znati prije nego počnete uzimati lijek OLANZAPINE CIPLA
It is important that you carry on taking OLANZAPINE CIPLA for as long as your doctor tells you. 
Važno je da nastavite uzimati lijek OLANZAPINE CIPLA onoliko dugo koliko Vam je liječnik rekao.
Studies in patients aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic parameters and increases in prolactin levels. 
Ispitivanja u bolesnika u dobi od 13 do 17 godina pokazala su različite nuspojave, uključujući povećanje tjelesne težine, promjene metaboličkih parametara te porast razina prolaktina.
Urinary incontinence, urinary retention Urinary hesitation11 
urinarna inkontinencija, urinarna retencija otežano mokrenje11
Olanzapine administered with lithium or valproate resulted in increased levels (10%) of tremor, dry mouth, increased appetite, and weight gain. 
Olanzapin primijenjen s litijem ili valproatom rezultirao je povećanim razinama ( 10%) tremora, suhoće usta, povećanjem apetita i povećanjem tjelesne težine.
You should not be given this medicine when breast-feeding, as small amounts of OLANZAPINE CIPLA can pass into breast milk. 
Ne biste smjeli uzimati ovaj lijek dok dojite, jer se male količine lijeka OLANZAPINE CIPLA mogu izlučiti u majčino mlijeko.
The starting dose and dose range need not be routinely altered for female patients relative to male patients. 
Početna doza i raspon doze ne moraju se rutinski mijenjati za bolesnice u usporedbi s muškim
Pharmadox Healthcare Limited KW20A Kordin Industrial Park Paola PLA 3000 
Pharmadox Zdravstvo Limited, KW20A Kordin Industrial Park, Paola, PLA 3000, Malta
If you take more OLANZAPINE CIPLA than you should Patients who have taken more OLANZAPINE CIPLA than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness. 
Ako uzmete više lijeka OLANZAPINE CIPLA nego što ste trebali Bolesnici koji su uzeli više lijeka OLANZAPINE CIPLA nego što su trebali imaju sljedeće simptome: ubrzan rad srca, uznemirenost/agresivnost, poteškoće s govorom, neuobičajene pokrete (osobito lica ili jezika) i sniženu razinu svijesti.
• If you have been previously diagnosed with eye problems such as certain kinds of glaucoma (increased pressure in the eye). 
• Ako od ranije imate dijagnosticirane tegobe s očima kao što su određene vrste glaukoma
In 44 patients with schizophrenia  65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events. 
U 44 bolesnika sa shizofrenijom u dobi iznad 65 godina doziranje od 5 do 20 mg/dan nije bilo povezano
OLANZAPINE CIPLA belongs to a group of medicines called antipsychotics and is used to treat the following conditions: 
OLANZAPINE CIPLA pripada skupini lijekova koji se zovu antipsihotici i koristi se za liječenje
If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotic medicines, including olanzapine must be discontinued. 
Ako se u bolesnika razviju znakovi i simptomi koji upućuju na NMS ili bolesnik dobije neobjašnjivu vrućicu bez dodatnih kliničkih manifestacija NMS-a, potrebno je prekinuti primjenu svih
The experience in adolescents (ages 13 to 17 years) is limited to short term efficacy data in schizophrenia (6 weeks) and mania associated with bipolar I disorder (3 weeks), involving less than 200 adolescents. 
Iskustvo u adolescenata (u dobi od 13 do 17 godina) ograničeno je na podatke o kratkotrajnoj djelotvornosti u shizofreniji (6 tjedana) i maniji povezanim s bipolarnim poremećajem I (3 tjedna), a obuhvatilo je manje od 200 adolescenata.
- The other ingredients are: - Tablet core: lactose monohydrate (See also end of section 2 - important information about some of the ingredients of Olanzapine Cipla), maize starch, hydroxypropyl cellulose, magnesium stearate. 
. - Ostali sastojci su : - Tablet jezgre : laktoza hidrat ( Vidi također kraj odjeljku 2 - Važne informacije o nekim od sastojaka Olanzapin Cipla ) , kukuruzni škrob, hidroksipropil celuloza , magnezijev stearat
Neuroleptic malignant syndrome (see section Discontinuation symptoms7, 12 
dizartrija neuroleptički maligni sindrom (vidjeti dio 4.4)12 simptomi ustezanja7, 12
Cipla (EU) Limited, Hillbrow House, Hillbrow Road, Esher, Surrey, KT10 9NW, UK Tel: +44 (0)1372 461407 
Nositelj odobrenja za stavljanje gotovog lijeka u promet Cipla (EU) Limited, Hillbrow House, Hillbrow Road, Esher, Surrey, KT10 9NW, UK Tel: +44 (0) 1372 461407
Tell your doctor. 
Provjerite sa svojim liječnikom
Marketing Authorisation Holder: Cipla (EU) Limited, Hillbrow House, Hillbrow Road, Esher, Surrey, KT10 9NW, UK 
Cipla (EU) Limited, Hillbrow House, Hillbrow Road, Esher, Surrey, KT10 9NW, UK
If a new manic, mixed, or depressive episode occurs, olanzapine treatment should be continued (with dose optimisation as needed), with supplementary therapy to treat mood symptoms, as clinically indicated. 
Ako dođe do nove manične, miješane ili depresivne epizode, liječenje olanzapinom treba nastaviti (uz optimizaciju doze prema potrebi) uz dopunsku terapiju za liječenje simptoma poremećaja
The following symptoms may occur in newborn babies, of mothers that have used OLANZAPINE CIPLA in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. 
Sljedeći simptomi mogu se pojaviti u novorođenčadi majki koje su koristile lijek OLANZAPINE CIPLA u posljednjem tromjesečju (zadnja tri mjeseca trudnoće): drhtanje, ukočenost mišića i/ili slabost, pospanost, uznemirenost, tegobe s disanjem te poteškoće u hranjenju.
In a multinational, double-blind, comparative study of schizophrenia, schizoaffective, and related disorders which included 1,481 patients with varying degrees of associated depressive symptoms (baseline mean of 16.6 on the Montgomery-Asberg Depression Rating Scale), a prospective secondary analysis of baseline to endpoint mood score change demonstrated a statistically significant improvement (p= 0.001) favouring olanzapine (-6.0) versus haloperidol (-3.1). 
U multinacionalnom, dvostruko slijepom, komparativnom ispitivanju shizofrenije, shizoafektivnih i povezanih poremećaja, koje je obuhvaćalo 1481 bolesnika s različitim stupnjevima pridruženih simptoma depresije (srednja početna vrijednost 16,6 po Montgomery-Asberg ljestvici depresije), prospektivna sekundarna analiza vrijednosti promjene raspoloženja od početnog do krajnjeg pokazala je statistički značajno poboljšanje (p=0,001) u korist olanzapina (-6,0) u odnosu na haloperidol (-3,1).
In patients with Parkinson's disease OLANZAPINE CIPLA may worsen the symptoms. 
U bolesnika koji boluju od Parkinsonove bolesti, OLANZAPINE CIPLA može pogoršati simptome.
Neonates exposed to antipsychotics (including olanzapine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. 
U novorođenčadi izloženoj antipsihoticima (uključujući olanzapin) tijekom trećeg tromjesečja trudnoće postoji rizik od nastanka nuspojava, uključujući ekstrapiramidne simptome i/ili simptome ustezanja koji nakon poroda mogu varirati po težini i trajanju.
Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of 7% from baseline body weight in 39.9% of patients. 
Dugotrajno liječenje olanzapinom (do 12 mjeseci) radi prevencije relapsa u bolesnika s bipolarnim poremećajem bilo je povezano s povećanjem tjelesne težine  7% od početne tjelesne težine u 39,9% bolesnika.
Patients with known risk for narrow-angle glaucoma. 
Bolesnici s poznatim rizikom za glaukom uskog kuta.
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed subsequent updates of the RMP. 
Nositelj odobrenja obavljat će dodatne farmakovigilancijske aktivnosti i intervencije detaljno objašnjene u dogovorenom Planu upravljanja rizikom, a koji je opisan u Modulu 1.8.2.
As a routine precaution, if you are over 65 years your blood pressure may be monitored by your doctor. 
Ako ste stariji od 65 godina, liječnik će Vam možda kao rutinsku mjeru opreza redovito kontrolirati
In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] ≥ 500 milliseconds [msec] at any time post baseline in patients with baseline QTcF < 500 msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo. 
U kliničkim ispitivanjima klinički značajna produljenja QTc intervala (Fridericia QT korekcija [QTcF] ≥ 500 milisekundi [ms] bilo kada nakon početne vrijednosti u bolesnika s početnom vrijednošću QTcF< 500 ms) bila su manje česta (0,1% do 1%) u bolesnika liječenih olanzapinom, bez značajnih razlika u povezanim srčanim događajima u usporedbi s placebom.
Absolute oral bioavailability relative to intravenous administration has not been determined 
Apsolutna bioraspoloživost peroralno primijenjenog lijeka u odnosu na intravensku primjenu nije ustanovljena.
Indigo carmine aluminium lake (E132) Brilliant blue FCF aluminium lake (E133) Iron oxide black (E172) 
Indigo karmin aluminija jezera (E132) Brilliant Blue FCF aluminija jezera (E133) Željezni oksid crni (E172) 6.2 Inkompatibilnosti
The daily dose of OLANZAPINE CIPLA is between 5 and 20 mg. 
Dnevna doza lijeka OLANZAPINE CIPLA iznosi između 5 i 20 mg.
In cytopenic dogs, there were no adverse effects on progenitor and proliferating cells in the bone marrow. 
U pasa s citopenijom nije bilo štetnih učinaka za matične i proliferacijske stanice
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. 
Ako Vam je liječnik rekao da ne podnosite neke šećere, prije uzimanja ovog lijeka obratite se svom
Each Olanzapine Cipla coated tablet contains either 2.5 mg, 5 mg, 7.5 mg, 10 mg or 15 mg of the active substance. 
-Djelatna tvar je olanzapin . Svaki Olanzapin Cipla obložena tableta sadržava ili 2,5 mg , 5 mg , 7.5 mg , 10 mg ili 15 mg aktivne tvari
Reversible effects consistent with elevated prolactin in rats included decreased weights of ovaries and uterus and morphologic changes in vaginal epithelium and in mammary gland. 
Reverzibilni učinci sukladni s porastom prolaktina u štakora uključivali su smanjenje težine jajnika i maternice te morfološke promjene epitela rodnice i
In the absence of detailed information on the pre-existing history of individual acute and tardive extrapyramidal movement disorders, it cannot be concluded at present that olanzapine produces less tardive dyskinesia and/or other tardive extrapyramidal syndromes. 
U nedostatku detaljnih informacija u anamnezi o prethodno postojećim individualnim akutnim i tardivnim ekstrapiramidalnih poremećajima kretanja, u ovom se trenutku ne može zaključiti da olanzapin dovodi do manje učestalosti tardivne diskinezije i/ili
Fatal outcomes have been reported for acute overdoses as low as 450 mg but survival has also been reported following acute overdose of approximately 2 g of oral olanzapine. 
Prijavljeni su smrtni ishodi kod akutnog predoziranja već pri maloj dozi od 450 mg, ali je opisano i preživljavanje nakon akutnog
Patients treated with any antipsychotic agents, including Olanzapine Cipla, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control. 
U bolesnika liječenih bilo kojim antipsihotikom, uključujući lijek OLANZAPINE CIPLA, treba pratiti pojavu znakova i simptoma hiperglikemije (kao što su polidipsija, poliurija, polifagija i slabost), a bolesnike s dijabetesom melitusom ili čimbenicima rizika za razvoj dijabetesa melitusa treba redovito pratiti zbog mogućeg pogoršanja glikemije.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. 
Bolesnici s rijetkim nasljednim poremećajem nepodnošenja galaktoze, nedostatkom Lapp-laktaze ili malapsorpcijom glukoze i galaktoze ne bi
Weight should be monitored regularly, e.g. at baseline, 4, 8 and 12 weeks after starting olanzapine treatment and quarterly thereafter. 
Redovito treba pratiti tjelesnu težinu, npr. na početku, 4, 8 i 12 tjedana nakon početka liječenja olanzapinom te svaka
Consult your doctor if your symptoms return but do not stop taking OLANZAPINE CIPLA unless your doctor tells you to. 
Ako Vam se simptomi vrate, posavjetujte se sa svojim liječnikom, ali nemojte prestati uzimati lijek OLANZAPINE CIPLA
In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher incidence of death and cerebrovascular adverse reactions compared to placebo (see also section 4.4). 
U kliničkim ispitivanjima u starijih bolesnika s demencijom liječenje olanzapinom bilo je povezano s povišenom incidencijom smrti i cerebrovaskularnih nuspojava u odnosu na placebo (vidjeti i dio 4.4).
OLANZAPINE CIPLA 2.5 mg coated tablets OLANZAPINE CIPLA 5 mg coated tablets OLANZAPINE CIPLA 7.5 mg coated tablets OLANZAPINE CIPLA 10 mg coated tablets OLANZAPINE CIPLA 15 mg coated tablets olanzapine 
OLANZAPINE CIPLA 2,5 mg obložene tablete OLANZAPINE CIPLA 5 mg obložene tablete OLANZAPINE CIPLA 7,5 mg obložene tablete OLANZAPINE CIPLA 10 mg obložene tablete OLANZAPINE CIPLA 15 mg obložene tablete
• The use of OLANZAPINE CIPLA in elderly patients with dementia is not recommended as it may have serious side effects. 
• Primjena lijeka OLANZAPINE CIPLA u starijih bolesnika s demencijom (zaboravljivošću) se ne preporučuje jer mogu nastati teške nuspojave.
In a study in breast feeding, healthy women, olanzapine was excreted in breast milk. 
U ispitivanju sa zdravim dojiljama olanzapin se izlučivao u majčino mlijeko.
In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma valproate levels. 
U jednom kliničkom ispitivanju u bolesnika s bipolarnom manijom, kombinacijska terapija valproatom i olanzapinom uzrokovala je incidenciju neutropenije od 4,1%; faktor koji je tome pridonio mogle su biti visoke razine valproata u plazmi.
OLANZAPINE CIPLA tablets contain lactose. 
OLANZAPINE CIPLA tablete sadrže laktozu.
Do not drink any alcohol if you have been given OLANZAPINE CIPLA as together with alcohol it may make you feel drowsy. 
Nemojte piti alkohol ako uzimate lijek OLANZAPINE CIPLA jer u kombinaciji s alkoholom može
• Weight gain has been seen in patients taking OLANZAPINE CIPLA. 
• Zapaženo je povećanje tjelesne težine u bolesnika koji uzimaju lijek OLANZAPINE CIPLA.
OLANZAPINE CIPLA has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment. 
Pokazalo se da OLANZAPINE CIPLA sprječava ponavljanje tih simptoma u bolesnika s bipolarnim poremećajem u kojih je epizoda manije reagirala na liječenje olanzapinom.
In placebo-controlled clinical trials (612 weeks duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5% vs. 1.5%, respectively). 
U placebom kontroliranim kliničkim ispitivanjima (trajanja od 6 do 12 tjedana) starijih bolesnika (srednja vrijednost dobi 78 godina) s psihozom i/ili poremećajima ponašanja uzrokovanih demencijom zabilježeno je dvostruko povećanje incidencije smrtnosti u bolesnika liječenih olanzapinom u usporedbi s bolesnicima koji su primali placebo (3,5% naspram 1,5%).
Activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60% and should be taken at least 2 hours before or after olanzapine. 
Aktivni ugljen smanjuje bioraspoloživost oralnog olanzapina za 50 do 60% te ga treba uzeti najmanje
12 Adverse event identified from spontaneous post-marketing reporting with frequency estimated at the upper limit of the 95% confidence interval utilising the Olanzapine Integrated Database. 
12 Nuspojava je identificirana iz spontanih prijava nakon stavljanja lijeka u promet, a učestalost je određena na gornjoj granici 95%-tnog intervala pouzdanosti uz pomoć integrirane baze podataka za
If you suddenly stop taking OLANZAPINE CIPLA, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur. 
Ako naglo prestanete s uzimanjem lijeka OLANZAPINE CIPLA mogu se pojaviti simptomi poput znojenja, nesanice, nevoljnog drhtanja, tjeskobe ili mučnine i povraćanja.
Transient, asymptomatic elevations of hepatic aminotransferases, ALT, AST have been seen commonly, especially in early treatment. 
Često su uočeni prolazni asimptomatski porasti vrijednosti jetrenih aminotransferaza, ALT) i AST, osobito u ranoj fazi liječenja.
Cold-formed aluminium blisters in cartons of 28 or 56 tablets per carton. 
Hladno formirane aluminijske plikovi u šteka 28 ili 56 tableta po kutiji.
However, as with other antipsychotics, caution should be exercised when olanzapine is prescribed with medicines known to increase QTc interval, especially in the elderly, in patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia. 
Međutim, kao i kod drugih antipsihotika, oprez je potreban prilikom propisivanja olanzapina s lijekovima za koje se zna da produljuju QTc-interval, osobito u starijih osoba, u bolesnika s prirođenim sindromom dugog QTintervala, kongestivnim zatajenjem srca, hipertrofijom srca, hipokalijemijom ili hipomagnezijemijom.
Some fatal cases have been reported in this particular group of patients. 
Prijavljeno je i nekoliko smrtnih slučajeva u
10 As assessed by measured values from clinical trials in the Olanzapine Integrated Database. 
10 Procijenjeno na temelju izmjerenih vrijednosti iz kliničkih ispitivanja u integriranoj bazi podataka za
(≥ 1.467 mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l< 1.467 mmol/l) to high (≥ 1.467 mmol/l). 
14 Uočeno za normalne početne razine triglicerida natašte (< 1,016 mmol/l) koje su porasle na visoke razine (≥ 1,467 mmol/l) i promjene u vrijednosti triglicerida natašte od početnih graničnih vrijednosti (≥ 1,016 mmol/l-< 1,467 mmol/l) do visokih vrijednosti (≥ 1,467 mmol/l).